Efficacy of Measuring Natural Killer-activating Receptor Ligands to Predict the Pathogenesis of Metabolic Dysfunction-associated Steatotic Liver Disease

Overview

Journal Hepatol Int

Publisher Springer

Specialty Gastroenterology

Date 2025 Mar 14

PMID 40085416

Authors

Jun Arai

Akinori Okumura

Satoshi Kimoto

Kazumasa Sakamoto

Tomoya Kitada

Rena Kitano

Tadahisa Inoue

Sayaka Nishimura

Noriko Inden

Yukiko Muraki

Naoya Kato

Kiyoaki Ito

Affiliations

Soon will be listed here.

Abstract

Objective: The proportion of non-B/non-C hepatocellular carcinoma cases is increasing, and the principal cause is metabolic dysfunction-associated steatotic liver disease (MASLD). The degree of intrahepatic natural killer (NK) cell infiltration has been reported to correlate with MASLD progression. However, reports on MASLD are limited. We aimed to investigate the involvement of NK cell-activating receptor ligands in MASLD pathogenesis.

Methods: This study cohort comprised 69 patients with biopsy-proven MASLD treated between 2012 and 2018 at our institute. The concentrations of major histocompatibility complex class I polypeptide-related sequences A and B (MICA and MICB, respectively) and B7H6 in patient sera were measured using enzyme-linked immunosorbent assay kits. Data were statistically compared between those with metabolic-associated steatotic liver (MASL, n = 25) and those with metabolic dysfunction-associated steatohepatitis (MASH, n = 44). The clinical characteristics related to higher concentrations of each NK cell-activating receptor ligand were also investigated.

Results: The MASH group had a higher level of the ligands than the MASL group. Furthermore, the MASH group had a significantly higher level of the Mac-2-binding protein glycosylation isomer (M2BPGi) than the MASL group (p < 0.001). MICA and MICB were positively correlated, and all three ligands were strongly correlated with alpha-fetoprotein and protein induced by vitamin K absence 2. Although MICB levels positively correlated with aspartate transaminase and alanine transaminase levels (p < 0.005), patients with higher MICA and B7H6 levels had higher M2BPGi levels. Interestingly, concentrations of B7H6 were significantly correlated with portal inflammation (p < 0.001), rather than lobular inflammation.

Conclusion: The three NK-activating receptor ligands were higher in the sera of the MASH group than those of the MASL group and strongly correlated with tumor markers, indicating the potential for hepatocarcinogenesis. Higher concentrations of serum B7H6 were correlated with advanced fibrosis and the degree of portal inflammation, which is a potential biomarker for predicting the pathogenesis of MASH.

References

Tateishi R, Uchino K, Fujiwara N, Takehara T, Okanoue T, Seike M . A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 update. J Gastroenterol. 2018; 54(4):367-376. PMC: 6437291. DOI: 10.1007/s00535-018-1532-5. View

Enomoto H, Akuta N, Hikita H, Suda G, Inoue J, Tamaki N . Etiological changes of liver cirrhosis and hepatocellular carcinoma-complicated liver cirrhosis in Japan: Updated nationwide survey from 2018 to 2021. Hepatol Res. 2024; 54(8):763-772. DOI: 10.1111/hepr.14047. View

Younossi Z, Paik J, Stepanova M, Ong J, Alqahtani S, Henry L . Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. J Hepatol. 2024; 80(5):694-701. DOI: 10.1016/j.jhep.2024.01.014. View

Suzuki H, Shimose S, Iwamoto H, Niizeki T, Kawaguchi T . Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD. Clin Mol Hepatol. 2024; 30(2):263-265. PMC: 11016480. DOI: 10.3350/cmh.2023.0557. View

Meyer M, Schwarzler J, Jukic A, Tilg H . Innate Immunity and MASLD. Biomolecules. 2024; 14(4). PMC: 11048298. DOI: 10.3390/biom14040476. View

Wang F, Zhang X, Liu W, Zhou Y, Wei W, Liu D . Activated Natural Killer Cell Promotes Nonalcoholic Steatohepatitis Through Mediating JAK/STAT Pathway. Cell Mol Gastroenterol Hepatol. 2021; 13(1):257-274. PMC: 8599163. DOI: 10.1016/j.jcmgh.2021.08.019. View

Kahraman A, Schlattjan M, Kocabayoglu P, Yildiz-Meziletoglu S, Schlensak M, Fingas C . Major histocompatibility complex class I-related chains A and B (MIC A/B): a novel role in nonalcoholic steatohepatitis. Hepatology. 2009; 51(1):92-102. DOI: 10.1002/hep.23253. View

Kahraman A, Fingas C, Syn W, Gerken G, Canbay A . Role of stress-induced NKG2D ligands in liver diseases. Liver Int. 2011; 32(3):370-82. DOI: 10.1111/j.1478-3231.2011.02608.x. View

Kumar V, Kato N, Urabe Y, Takahashi A, Muroyama R, Hosono N . Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet. 2011; 43(5):455-8. DOI: 10.1038/ng.809. View

10.

Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T . Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci U S A. 1996; 93(22):12445-50. PMC: 38011. DOI: 10.1073/pnas.93.22.12445. View

11.

Myers J, Miller J . Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2020; 18(2):85-100. PMC: 8316981. DOI: 10.1038/s41571-020-0426-7. View

12.

Arai J, Okumura A, Kato N, Ito K . Natural killer group 2D-major histocompatibility complex class I polypeptide-related sequence A activation enhances natural killer cell-mediated immunity against hepatocellular carcinoma: A review. Hepatol Res. 2024; 54(5):420-428. DOI: 10.1111/hepr.14038. View

13.

Chen L, Feng J, Xu B, Zhou Y, Zheng X, Wu C . B7-H6 expression in human hepatocellular carcinoma and its clinical significance [corrected]. Cancer Cell Int. 2018; 18:126. PMC: 6122564. DOI: 10.1186/s12935-018-0627-7. View

14.

Kiyoaki I, Sumida Y, Nakade Y, Okumura A, Nishimura S, Ibusuki M . Mac-2 binding protein glycosylation isomer, the FIB-4 index, and a combination of the two as predictors of non-alcoholic steatohepatitis. PLoS One. 2022; 17(11):e0277380. PMC: 9648718. DOI: 10.1371/journal.pone.0277380. View

15.

Rinella M, Lazarus J, Ratziu V, Francque S, Sanyal A, Kanwal F . A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023; 78(6):1966-1986. PMC: 10653297. DOI: 10.1097/HEP.0000000000000520. View

16.

Matteoni C, Younossi Z, Gramlich T, Boparai N, Liu Y, McCullough A . Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999; 116(6):1413-9. DOI: 10.1016/s0016-5085(99)70506-8. View

17.

Kleiner D, Brunt E, Van Natta M, Behling C, Contos M, Cummings O . Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6):1313-21. DOI: 10.1002/hep.20701. View

18.

Sterling R, Lissen E, Clumeck N, Sola R, Correa M, Montaner J . Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006; 43(6):1317-25. DOI: 10.1002/hep.21178. View

19.

Kuno A, Ikehara Y, Tanaka Y, Ito K, Matsuda A, Sekiya S . A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep. 2013; 3:1065. PMC: 3545220. DOI: 10.1038/srep01065. View

20.

Arai J, Goto K, Stephanou A, Tanoue Y, Ito S, Muroyama R . Predominance of regorafenib over sorafenib: Restoration of membrane-bound MICA in hepatocellular carcinoma cells. J Gastroenterol Hepatol. 2017; 33(5):1075-1081. DOI: 10.1111/jgh.14029. View